Compare Biogen Inc (BIIB) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Valero Energy Corporation — how do they compare? Biogen Inc trades at $206.54 (market cap $30.13B), while Valero Energy Corporation trades at $328.53 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 3.1× Biogen Inc's market cap, and Valero Energy Corporation pays a 1.48% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | VLO | |
|---|---|---|
Market Cap | $30.13B | $93.27B |
Sector | Health | Energy |
52-Week High | $216.63 | $323.92 |
52-Week Low | $128.93 | $133.38 |
Enterprise Value | $37.20B | $96.74B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Valero Energy (VLO) trades at $328.43, up 4.28% today, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with key resistance at $329 and support at $319. Recent Q2 2026 results significantly exceeded expectations with EPS of $12.54 versus $10.11 estimates, driven by robust refining margins and renewable diesel performance. Revenue trends show recovery from 2025's $122.7B to projected $139.4B in 2026.
VLO presents a compelling value opportunity with attractive valuation metrics (P/E 13.51, P/S 0.7) and strong profitability (ROE 29.31%). Analyst consensus favors Buy ratings (55.55%) with $324.27 price target. Key risks include refining margin volatility and geopolitical impacts on oil markets. The company's disciplined capital allocation and dividend payments ($1.20 quarterly) provide shareholder returns amid energy sector transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
